MBX Biosciences Inc Stock Price, News & Analysis

MBX Biosciences has appointed Dr. Andreas Moraitis as Senior Vice President of Clinical Development. Dr. Moraitis, a board-certified endocrinologist, brings extensive experience in leading clinical development programs for endocrine and metabolic conditions. He previously spent over a decade at Corcept Therapeutics overseeing endocrine clinical development and supporting the NDA filing of relacorilant. At MBX, he will lead clinical development for canvuparatide, the company's lead product candidate for hypoparathyroidism. Dr. Moraitis's background includes serving as Clinical Assistant Professor at the University of Michigan's Endocrine Oncology Program and completing a fellowship at the National Institutes of Health. His appointment strengthens MBX's leadership team as they advance their pipeline of obesity and rare disease treatments.

MBX Biosciences (Nasdaq: MBX) has submitted an Investigational New Drug (IND) application to the FDA for MBX 4291, a novel long-acting GLP-1/GIP receptor co-agonist prodrug designed for obesity treatment. The drug candidate aims to be administered once monthly, leveraging MBX's proprietary PEP platform technology. Upon IND clearance, the company plans to initiate Phase 1 trials in healthy overweight volunteers during Q3 2025. MBX 4291 is being developed as a potential best-in-class treatment, with anticipated benefits including less frequent dosing and improved gastrointestinal tolerability, which could lead to better patient adherence and enhanced weight loss outcomes. The company is also advancing multiple early-stage obesity candidates using their precision peptide platform.

MBX Biosciences announced two presentations at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. The presentations focus on MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, showcasing its safety, pharmacokinetics, and pharmacodynamics in healthy volunteers from a Phase 1 trial, as well as its effects on blood glucose in rats. The findings demonstrate MBX 1416's potential as a once-weekly treatment for post-bariatric hypoglycemia (PBH). The company previously reported positive topline results from a Phase 1 SAD/MAD trial and plans to initiate a Phase 2 trial in the second half of 2025.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in June 2025. CEO Kent Hawryluk will present at the Jefferies Global Healthcare Conference in New York on June 4 at 2:00 p.m. ET, and at the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET. Live webcasts will be available on the company's investor website, with replays accessible for approximately 90 days after the events.

MBX Biosciences reported Q1 2025 financial results and corporate updates. The company has $240.8 million in cash and equivalents, expected to fund operations into mid-2027. Key highlights include:

- Phase 2 Avail trial for canvuparatide in hypoparathyroidism completed enrollment with 64 participants, with topline results expected in Q3 2025

- IND submission for MBX 4291, a once-monthly GLP-1/GIP co-agonist prodrug for obesity treatment, planned for Q2 2025

- Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia to begin in H2 2025

Financial results show R&D expenses increased to $22.4 million (vs $11.0M in Q1 2024), G&A expenses rose to $4.1 million (vs $2.3M), with a net loss of $23.9 million (vs $12.3M).

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in May 2025.

The company's President and CEO, Kent Hawryluk, will present at the Citizens Life Sciences Conference on May 7, 2025 (3:00-3:25 p.m. ET) and the RBC 2025 Global Healthcare Conference on May 21, 2025 (3:35-4:00 p.m. ET). Both events will be held in New York and will feature fireside chats along with one-on-one meetings.

Investors can access live webcasts of both presentations through the company's website at investors.mbxbio.com/news-events/events. Replay recordings will be available approximately two hours after each event and remain accessible for 90 days.

MBX Biosciences (Nasdaq: MBX) has appointed Steve Hoerter as an independent director to its Board of Directors. Hoerter brings over 30 years of pharmaceutical commercialization and executive leadership experience to the clinical-stage biopharmaceutical company.

Most recently, Hoerter served as President, CEO and Director of Deciphera Pharmaceuticals until its $2.4 billion acquisition by Ono Pharmaceutical in 2024. His previous roles include senior commercial leadership positions at Agios Pharmaceuticals, Clovis Oncology, Roche, and Genentech.

The appointment aims to support MBX's advancement of its pipeline focused on endocrine and metabolic disorders, including programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company leverages its Precision Endocrine Peptides™ technology platform.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's President and CEO, Kent Hawryluk, will deliver a podium presentation on Monday, April 7, 2025, from 8:00 a.m. to 8:40 a.m. ET. The presentation will be accompanied by one-on-one meetings.

Investors can access the live webcast through the investors section of MBX Biosciences' website at investors.mbxbio.com/news-events/events. A replay will be available approximately two hours after the event and will remain accessible for about 90 days on the company's website.

MBX Biosciences (Nasdaq: MBX) has announced its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company completed enrollment of 64 patients in its Phase 2 Avail™ trial of canvuparatide for hypoparathyroidism, with topline results expected in Q3 2025.

Key developments include positive Phase 1 results for MBX 1416 in post-bariatric hypoglycemia, with Phase 2 trials planned for 2H 2025. The company is also preparing an IND submission for MBX 4291, their obesity treatment candidate, in Q2 2025.

Financial highlights:

• Cash position: $262.1M as of December 31, 2024
• R&D expenses: $57.4M for 2024 (up from $28.5M in 2023)
• G&A expenses: $10.8M for 2024 (up from $6.8M in 2023)
• Net loss: $61.9M for 2024 (increased from $32.6M in 2023)

Current cash runway expected to support operations into mid-2027.